TGH Ventures

Investment decisions are made by Tampa General Hospital's senior executive leadership rather than a standalone venture team with independent authority. The hospital's chief strategy officer and innovation officers evaluate opportunities based on clinical alignment, pilot feasibility within TGH's network, and strategic fit with the health system's long-term care-delivery goals. No dedicated external investment committee structure has been publicly disclosed.

Deal flow originates primarily through Tampa General's clinical and operational networks — physician-entrepreneurs, academic collaborators at the University of South Florida, med-tech conferences, and inbound referrals from portfolio-company founders. The hospital's status as a major safety-net and academic medical center in Florida creates a natural gravity for early-stage companies seeking an enterprise hospital pilot site, which doubles as the venture arm's sourcing funnel.

TGH Ventures invests directly from the hospital's corporate balance sheet. There is no external fund vehicle with limited partners. This structure gives the health system full discretion over investment pacing, check size, and hold periods, without the fundraising cycle constraints or LP-communication obligations of a traditional venture fund.

The firm targets seed through late-stage venture rounds, though its anchor-customer model is most effective at the early stages — pre-revenue to Series B — where a single enterprise hospital contract can materially de-risk a startup's commercialization path. Later-stage investments are made selectively, typically where Tampa General intends to serve as a multi-year deployment partner.

TGH Ventures does not invest in therapeutic drug development, medical-device manufacturing, or biotech platforms where FDA regulatory timelines exceed the health system's strategic horizon. The portfolio is concentrated in enterprise software, digital health platforms, and care-delivery innovation where a hospital operator's operating data, clinical workflows, and patient volume directly inform product development and go-to-market execution.

The Tampa General Hospital Foundation is a separate 501(c)(3) entity that raises philanthropic funds for clinical programs, research grants, capital projects, and community health. TGH Ventures is a corporate investment function of the hospital itself, not a fund housed within the foundation. The two entities maintain separate governance, and no philanthropic dollars are deployed through the venture arm.

Yes, TGH Ventures participates in syndicated rounds alongside institutional VC firms, particularly when a portfolio company can benefit from both traditional venture expertise and the hospital's clinical-deployment capacity. The health system's anchor-customer commitment often serves as a valuable signal to co-investors evaluating go-to-market risk in regulated healthcare environments.